Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (09) : 893-897     DOI: 10.3971/j.issn.1000-8578.2021.21.0424
Advances in Application of PDT Combined with Multiple Therapies on Unresectable Extrahepatic Cholangiocarcinoma
HE Puyi1, LI Xuemei1, WANG Yunpeng1, XU Bo1, WANG Haiyun1, ZHANG Jing1, PU Weigao1, CHEN Hao1,2,3#br#
1. Second Clinical Medical College of Lanzhou University, Lanzhou 730030, China; 2. Surgery of Oncology, Second Hospital of Lanzhou University, Lanzhou 730030, China; 3. Key Laboratory of Digestive System Oncology, Second Hospital of Lanzhou University, Lanzhou 730030, China
Download: PDF(2814 KB)   ( 51 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Cholangiocarcinoma is a malignant tumor originating from the bile duct epithelium, with the increasing incidence year by year. Its early symptoms are atypical and the diagnosis rate is low. Most of the patients are already in advanced stage when they are diagnosed, losing the best surgery period. Currently, the conservative treatments for unresectable extrahepatic cholangiocarcinoma include stent placement, radiofrequency ablation, radiotherapy and chemotherapy, targeted and immunotherapy and other systemic treatments. But due to the high malignancy of biliary tract tumors, the tendency to develop drug resistance and the limited population benefited from the emerging treatment modalities, we urgently need to explore new treatment strategies to break this bottleneck. As a new treatment for cholangiocarcinoma, photodynamic therapy has attracted much attention for its clinical application and therapeutic effects. In this paper, we summarize the principles of photodynamic therapy, the combination of photodynamic and other therapeutic modalities, especially the combination of photodynamic with emerging immune and targeted therapies, and describe the current hotspot directions of photodynamic therapy research at home and abroad to provide reference for clinical treatment and research.
Keywords Cholangiocarcinoma      Photodynamic therapy      Metal stents      Chemotherapy      Targeted therapy      Immunotherapy
ZTFLH:  R735.8  
Fund:Key Talents Project of Gansu Province (No. 2019RCXM020); Key Project of Science and Technology in Gansu province (No. 19ZD2WA001); Science and Technology Project of Chengguan District of Lanzhou City (No. 2019RCCX0034, 2020SHFZ0039, 2020JSCX0073); Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (No. CY2017-ZD01)
Issue Date: 14 September 2021
 Cite this article:   
HE Puyi,LI Xuemei,WANG Yunpeng, et al. Advances in Application of PDT Combined with Multiple Therapies on Unresectable Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 893-897.
E-mail this article
E-mail Alert
Articles by authors
HE Puyi
LI Xuemei
WANG Yunpeng
WANG Haiyun
PU Weigao
[1] Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma
2020: the next horizon in mechanisms and management[J]. Nat
Rev Gastroenterol Hepatol, 2020, 17(9): 557-588.
[2] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma:
Epidemiology and risk factors[J]. Liver Int, 2019, 39 Suppl 1:
[3] Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis
and Treatment of Cholangiocarcinoma[J]. Curr Gastroenterol Rep,
2017, 19(1): 2.
[4] Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management
of cholangiocarcinoma[J]. Gastroenterology, 2013, 145(6):
[5] Mansoori B, Mohammadi A, Amin Doustvandi M, et al.
Photodynamic therapy for cancer: Role of natural products[J].
Photodiagnosis Photodyn Ther, 2019, 26: 395-404.
[6] Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic
therapy-mechanisms, photosensitizers and combinations[J].
Biomed Pharmacother, 2018, 106: 1098-1107.
[7] Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy
for nonresectable cholangiocarcinoma: a randomized prospective
study[J]. Gastroenterology, 2003, 125(5): 1355-1363.
[8] Cheon YK, Lee TY, Lee SM, et al. Longterm outcome of
photodynamic therapy compared with biliary stenting alone
in patients with advanced hilar cholangiocarcinoma[J]. HPB
(Oxford), 2012, 14(3): 185-193.
[9] Kahaleh M, Mishra R, Shami VM, et al. Unresectable
cholangiocarcinoma: comparison of survival in biliary stenting
alone versus stenting with photodynamic therapy[J]. Clin
Gastroenterol Hepatol, 2008, 6(3): 290-297.
[10] Moole H, Tathireddy H, Dharmapuri S, et al. Success of
photodynamic therapy in palliating patients with nonresectable
cholangiocarcinoma: A systematic review and meta-analysis[J].
World J Gastroenterol, 2017, 23(7): 1278-1288.
[11] Hong MJ, Cheon YK, Lee EJ, et al. Long-term outcome of
photodynamic therapy with systemic chemotherapy compared
to photodynamic therapy alone in patients with advanced hilar
cholangiocarcinoma[J]. Gut Liver, 2014, 8(3): 318-323.
[12] Wentrup R, Winkelmann N, Mitroshkin A, et al. Photodynamic
Therapy Plus Chemotherapy Compared with Photodynamic
Therapy Alone in Hilar Nonresectable Cholangiocarcinoma[J].
Gut Liver, 2016, 10(3): 470-475.
[13] Fuks D, Bartoli E, Delcenserie R, et al. Biliary drainage,
photodynamic therapy and chemotherapy for unresectable
cholangiocarcinoma with jaundice[J]. J Gastroenterol Hepatol,
2009, 24(11): 1745-1752.
[14]Capella MA, Capella LS. A light in multidrug resistance:
photodynamic treatment of multidrug-resistant tumors[J]. J
Biomed Sci, 2003, 10(4): 361-366.
[15] 张良强, 王志刚, 潘乐玉, 等. 分子靶向药物治疗胆管癌的研究
进展[J]. 癌症进展, 2020, 18(19): 1974-1978, 2029. [Zhang LQ,
Wang ZG, Pan LY, et al. Research progress of molecular targeted
drugs for bile duct cancer[J]. Ai Zheng Jin Zhan, 2020, 18(19):
1974-1978, 2029.]
[16] Gomer CJ, Ferrario A, Luna M, et al. Photodynamic
therapy: combined modality approaches targeting the tumor
microenvironment[J]. Lasers Surg Med, 2006, 38(5): 516-521.
[17] Kim SG, Hong JW, Boo SH, et al. Combination treatment of
Cetuximab and photodynamic therapy in SNU-1041 squamous
cancer cell line[J]. Oncol Rep, 2009, 22(4): 701-708.
[18] Bhuvaneswari R, Yuen GY, Chee SK, et al. Antiangiogenesis
agents avastin and erbitux enhance the efficacy of photodynamic
therapy in a murine bladder tumor model[J]. Lasers Surg Med,
2011, 43(7): 651-662.
[19] Ferrario A, Gomer CJ. Avastin enhances photodynamic therapy
treatment of Kaposi's sarcoma in a mouse tumor model[J]. J
Environ Pathol Toxicol Oncol, 2006, 25(1-2): 251-259.
[20] Makowski M, Grzela T, Niderla J, et al. Inhibition of
cyclooxygenase-2 indirectly potentiates antitumor effects of
photodynamic therapy in mice[J]. Clin Cancer Res, 2003, 9(14):
[21] Beltrán Hernández I, Yu Y, Ossendorp F, et al. Preclinical and
Clinical Evidence of Immune Responses Triggered in Oncologic
Photodynamic Therapy: Clinical Recommendations[J]. J Clin
Med, 2020, 9(2): 333.
[22] Falk-Mahapatra R, Gollnick SO. Photodynamic Therapy and
Immunity: An Update[J]. Photochem Photobiol, 2020, 96(3):
[23] Chen WR, Liu H, Ritchey JW, et al. Effect of different components
of laser immunotherapy in treatment of metastatic tumors in
rats[J]. Cancer Res, 2002, 62(15): 4295-4299.
[24] Chen WR, Korbelik M, Bartels KE, et al. Enhancement of laser
cancer treatment by a chitosan-derived immunoadjuvant[J].
Photochem Photobiol, 2005, 81(1): 190-195.
[25] 刘朝莲, 吴宏磊, 徐可. 光动力疗法与抗肿瘤免疫治疗在肿瘤
治疗中的应用[J]. 中国肿瘤临床, 2021, 48(1): 35-39. [Liu CL,
Wu HL, Xu K. Photodynamic therapy and the application of antitumor
immunotherapy for tumor treatment[J]. Zhongguo Zhong
Liu Lin Chuang, 2021, 48(1): 35-39.]
[26] St Denis TG, Aziz K, Waheed AA, et al. Combination approaches
to potentiate immune response after photodynamic therapy for
cancer[J]. Photochem Photobiol Sci, 2011, 10(5): 792-801.
[27] Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint
inhibitors: recent progress and potential biomarkers[J]. Exp Mol
Med, 2018, 50(12): 1-11.
[28] de Miguel M, Calvo E. Clinical Challenges of Immune Checkpoint
Inhibitors[J]. Cancer Cell, 2020, 38(3): 326-333.
[29] Kleinovink JW, Fransen MF, L?wik CW, et al. Photodynamic-
Immune Checkpoint Therapy Eradicates Local and Distant
Tumors by CD8+ T Cells[J]. Cancer Immunol Res, 2017, 5(10):
[30] Cramer GM, Moon EK, Cengel KA, et al. Photodynamic Therapy
and Immune Checkpoint Blockade[J]. Photochem Photobiol,
2020, 96(5): 954-961.
[31] O'Shaughnessy MJ, Murray KS, La Rosa SP, et al. Systemic
Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by
Vascular-Targeted Photodynamic Therapy of Primary Tumors[J].
Clin Cancer Res, 2018, 24(3): 592-599.
[32] Austin JW, Lu P, Majumder P, et al. STAT3, STAT4, NFATc1, and
CTCF regulate PD-1 through multiple novel regulatory regions in
murine T cells[J]. J Immunol, 2014, 192(10): 4876-4886.
[33] Chan LC, Li CW, Xia W, et al. IL-6/JAK1 pathway drives PD-L1
Y112 phosphorylation to promote cancer immune evasion[J]. J
Clin Invest, 2019, 129(8): 3324-3338.
Related articles from Frontiers Journals
[1] MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui. Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 937-943.
[2] CHEN Zegang, WANG Yongbing, OU Tao. Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 982-986.
[3] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[4] HUANG Xixiang, CAI Xiaoxuan, WANG Tianji, HUANG Miaoen, LI Li, LYU Yingnian, . Phototoxicity of Pheophorbide A Extracted from Gracilaria Lemaneiformis on Six Kinds of Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 780-785.
[5] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[6] CHEN Yarui, WANG Jiangtao, GUAN Quanlin, JI Wei, JIAO Fuzhi. Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 855-860.
[7] WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin. Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 698-702.
[8] ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 505-513.
[9] SUN Junzhao, CHENG Gang, ZHANG Jianning. Advances in Treatment of Brain Metastasis from Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 522-527.
[10] ZHANG Yu, HE Kunyu, FENG Shiyu. Current Progress in Treatment of Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 528-534.
[11] GUO Yang, WU Suqing, WEN Zhaohui. Application Progress of Metal-organic Frameworks in Tumors Therapy[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 472-477.
[12] XIE Zhanghong, HUA Qingquan. Research Progress of Ferroptosis in Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 282-287.
[13] FAN Bingjie, CHANG Yu, LIU Xiyang, ZHANG Mingzhi, ZHANG Lei. Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 205-212.
[14] ZHANG Haodong, WEI Fengxian, ZHANG Chunfang, XU Xiaodong. Clinical Value of Platelet and Its Parameters Combined with Tumor Markers in Preoperative Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 213-218.
[15] YIN Detao, ZHANG Pengyu. Comprehensive Treatment of Anaplastic Thyroid Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(02): 85-89.
Full text